Clinical Trial Update: A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel and carboplatin with necitumumab in stage IV squamous non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Necitumumab (necitumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2019-02-12